1 / 8

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Fo

Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

bharatbookseo
Download Presentation

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Fo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022

  2. Summary Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  3. HighlightsKey Questions Answered- How will the CML market size and composition change over the forecast period? - How will the TKIs be used differently in lines of therapy and in different patient segments?- The unmet needs of many CML patients are relatively low. What remaining needs exist, and what qualities must potential new market entrants have to compete in this space?- Will the entry of generic imatinib influence physician prescribing patterns? Why or why not?- What are the strengths and weaknesses of Gleevec, Tasigna, Sprycel, Bosulif, Iclusig and Synribo, and how do they stack up against one another? Which will have the greatest commercial success over the forecast period?- Do key opinion leaders believe that discontinuation of TKI therapy is feasible? For which patients? W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  4. Key Findings- Global pressure to cut healthcare expenditure will influence physicians’ prescribing patterns.- Once launched, generic imatinib will be the most commonly prescribed first line therapy for chronic phase patients, the largest and most lucrative segment. This availability of generics will be the single greatest factor in the decline of the CML therapeutics market from 2012-2022.- Of the recent market entrants Bosulif and Iclusig, Iclusig will be more commercially successful. It is a favorite of KOLs because of its potent efficacy, particularly in patients with the T315I mutation. However, the uptake of both drugs will be restricted due to high prices and concerns about long-term side effects.- There is still significant unmet need for safe and effective therapies that can control CML in the accelerated and blast phases. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  5. Scope- Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized CML therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CML therapeutics market - Pipeline analysis: The CML pipeline is exceptionally weak, due to the relatively low level of unmet need. Innovative early-stage projects are highlighted, supplemented with KOL opinions about the validity of new targets. - Analysis of the current and future market competition in the global CML market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  6. Reasons to buy  Develop business strategies by understanding the trends shaping and driving the global CML therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CML therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Forecast drug sales in the global CML therapeutics market from 2012-2022. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.  W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  7. Table of Contents Introduction Disease Overview Epidemiology Disease Management Opportunity and Unmet Need Pipeline Assessment Current and Future Players Market Outlook W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

  8. To view the full Executive Summary and Table of Contents, please visit: PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022 Contact Us:-Call India: +91-22-27810772/73Email id : info@bharatbook.comWebsite : www.bharatbook.comOur Blog : https://www.bharatbook.com/blog/ Follow Us On :

More Related